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1. Introduction 
Peptic ulcer formation in either the stomach or duedonum is due to an imbalance between 
erosive factors such as hydrochloric acid and pepsin and the ability of the gastroduodenal 
mucosal to protect and heal itself (1). Unlike duedonal ulcers, in which the importance of 
acid secretion is indisputable, gastric ulcers can develop despite only minimal amounts of 
acid. 
On the other hand, it has become apparent that consumption of nonsteroidal anti-
inflammatory drugs (NSAIDs) and stomach colonization by Helicobacter pylori (H.pylori) 
are the two most common causes of peptic ulcer disease. The prevention and management 
of NSAID related gastrointestinal (GI) complications are well recognized and in many cases 
successfully treated. However, the understanding and treatment of H. pylori-induced ulcers 
are still in progress (2).  
2. NSAIDs induced gastric ulcers 
NSAIDs are mainly indicated for mild to moderate pain of somatic origin. Due to their anti-
inflammatory effect, they are among the agents most frequently used against 
musculoskeletal and rheumatic disorders throughout the world (3). Other indications 
include osteoarthritis, soft-tissue injury, renal colic, postoperative pain, and dental 
procedures. The efficacy of NSAIDs may vary by patient and by indication. In case of 
inefficacy, substitution by a NSAID from a different chemical class is a reasonable 
therapeutic option. 
In 1899, acetylsalicylic acid was released to the pharmaceutical market (4). Almost 40 years 
passed before it was realized that aspirin may damage the gastric mucosa (5). Later, drugs 
having similar effects were recognized and thus termed `aspirin-like drugs' or NSAIDs. The 
main therapeutic actions proved to be analgesic, antipyretic and anti-inflammatory through 
inhibition of the cyclooxygenase (COX) enzyme system (6,7). During the past 15 years the 
number of NSAIDs has doubled. Along with the discovery in 1990 of the inducible form of 
the cyclooxygenase system, i.e. COX-2 (8), and development of COX-2-specific inhibitors, 
NSAIDs may now be classified as either (i) non-selective NSAIDs, i.e. aspirin and non-
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aspirin NSAIDs; (ii) COX-2 preferential inhibitors; and (iii) COX-2-specific inhibitors 
(coxibs) or COX-1-sparing NSAIDs (9).  
NSAIDs may be grouped as salicylates (with as prominent member aspirin itself), 
arylalkanoic acids (diclofenac, indomethacin, nabumetone, sulindac), 2-arylproprionic acids 
or profens (ibuprofen, flurbiprofen, ketoprofen, naproxen), N-arylanthranilic acids or 
fenamic acids (mefenamic acid, meclofenamic acid), pyrazolidine derivates 
(phenylbutazone), oxicams (piroxicam, meloxicam), sulfonanilides (nimesulide), and others 
(10). As a group, NSAIDs are structurally diverse and differ in pharmacokinetic and 
pharmacodynamic properties, but ultimately they share the same mode of action. Like 
aspirin, nonaspirin NSAIDs inhibit the production of prostaglandins by blocking the COX 
enzyme, causing analgesic, antipyretic, and anti-inflammatory benefits, but at a risk for 
increased gastric bleeding (11). Two COX isoforms have been identified and referred as 
COX-1 and COX-2. The inducible COX-2 is an important regulator to generate 
prostaglandins that mediate inflammation and pain, whereas the constitutive COX-1 is 
responsible for maintenance of the integrity of gastric mucosa and platelet aggregation (1).  
However, aspirin and nonaspirin NSAIDs differ fundamentally in the way the COX enzyme 
is inhibited. Aspirin inhibits COX by noncompetitive and irreversible acetylation, where an 
acetyl group is covalently attached to a serine residue in the active site of the COX enzyme, 
rendering the COX enzyme permanently inaccessible for the biotransformation of 
arachidonic acid into PG H2. 
Conversely, nonaspirin NSAIDs competitively and reversibly inhibit the COX enzyme 
during only part of their dosage interval. This distinction is exemplified by their differential 
effects on platelet aggregation (10).  
The gastroduodenal adverse effects include dyspepsia without endoscopically proven 
damage, asymptomatic endoscopic lesions of submucosal haemorrhage, erosions and ulcers, 
and-most important-ulcer complications (3). It is highly likely that the ulcerogenic effects of 
NSAIDs are directly related to their ability to suppress prostaglandin synthesis in the 
stomach. Prostaglandins play an important role in the GI tract: they mediate several 
components of mucosal defence (blood flow, mucus and bicarbonate secretion and mucosal 
immunocyte function). There is a good correlation between the ability of an NSAID to 
suppress gastric prostaglandin synthesis and its ulcerogenic action. NSAIDs, including 
acetyl salicylic acid, also have topical irritant properties that may contribute to their ability 
to damage the gastric mucosa. The majority of NSAIDs are weak acids with an ionisation 
constant in the range of 3.5. In the strongly acid environment of gastric juice, drugs are non-
ionized and freely cross the cell membrane into the mucosal cells. The elevated intracellular 
pH promotes dissociation to its ionized form with subsequent intra-epithelial accumulation. 
The phenomenon of ion trapping and/or ability of these drugs to uncouple oxidative 
phosphorylation represent two important steps in the topical irritancy of NSAIDs. Thus, 
intragastric acidic pH plays an important role in the topical or systemic adverse effects of 
NSAIDs on the gastroduodenal mucosa (12). 
Established risk factors for NSAID-associated ulcer complications include patient-specific 
factors such as advanced age, female gender, a history of peptic ulcer, and drug-specific 
factors such as the use of non-selective NSAIDs (type, dose, duration, multiple use) and 
concomitant anticoagulant drugs or corticosteroids. Probable risk factors comprise H.pylori 
infection and heavy consumption of alcohol, whereas use of selective serotonin re-uptake 
inhibitors, smoking and a number of other factors have also been proposed to contribute. 
Knowledge of absolute risk estimates is important for clinical decision making (3).  
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There is consistently clear evidence that advanced age is a major risk factor for complicated 
ulcer disease. The risk increases at least linearly with age in both NSAID-unexposed and 
NSAID-exposed individuals (13,14). 
There is good evidence from meta-analysis that males have a two-fold higher risk of ulcer 
complications compared to females (15). However, among NSAID users, women have both 
a greater relative risk (RR) than men (RR 5.0 versus. 3.5) (15) and a higher absolute risk, with 
number needed to harm (NNH) among women being about 50 versus 75 in men (13).  
Patients with a history of peptic ulcer have an overall almost six-fold increased risk of ulcer 
complications (15, 16). Even though the relative risk of NSAID use is lower in patients 
without a history of ulcers than in patients with a prior ulcer (odds ratio (OR) 5.0 versus 2.5), 
NSAIDs are still more dangerous (17) due to the higher base-line risk of ulcer complications 
among the latter.  
Heavy alcohol use was found to be associated with an increased risk of bleeding peptic ulcer 
(18,19). Previous dyspepsia may be associated with an increased risk of ulcer complications 
(20). NSAID-related dyspepsia is often treated with a proton pump inhibitor to heal a 
possible underlying ulcer. Some data suggest that the use of H2-receptor antagonists can 
mask dyspepsia that may herald an ulcer bleeding. In clinical practice, therefore, proton 
pump inhibitors are often preferred (3). 
The interaction between H. pylori and the use of NSAIDs in the development of 
gastroduodenal ulcers is less clear. H. pylori infection and NSAID use may represent 
independent but synergistic risk factors (21,22). A recent meta-analysis of 21 studies that 
evaluated the relationship between H. pylori and NSAIDs in the development of 
gastroduodenal ulcers found that the risk for uncomplicated ulcers was 4 times as high in H. 
Pylori positive compared with H. pylori-negative patients, irrespective of NSAID use (OR, 
4.03), and 3 times as high in NSAID users compared with nonusers, irrespective of H. pylori 
status (OR, 3.10) (22). Furthermore, the risk of uncomplicated ulcers was almost twice as 
high among H. pylori-positive compared with H. Pylori-negative NSAID users (OR, 1.81), 
and 17.5 times higher among H. pylori-positive NSAID users compared with H. pylori-
negative nonusers. Possible explanations for the increased risk of ulcers in H. pylori-positive 
NSAID users are deterioration of the mucosal barrier caused by inflammation, increased 
acid secretion, a higher level of apoptosis in the infected mucosa, and decreased gastric 
adaptation to NSAIDs (23).  
Patients with rheumatoid arthritis seem to be at increased risk of having ulcer complications 
compared with patients with osteoarthritis (24). This difference may, however, be explained 
at least partly by use of higher doses of NSAIDs in patients with rheumatoid arthritis. Some 
studies have indicated that patients with a history of heart failure are at increased risk of 
ulcer complications (25). Moreover, recent data suggest that diabetes mellitus may increase 
the risk as well (20).  
Solid evidence from landmark studies (26, 14), and good meta-analyses (15, 16) indicate that 
the use of ibuprofen and diclofenac is associated with a lower risk of gastroduodenal 
adverse effects. The use of naproxen, indomethacin and aspirin constitutes an intermediate 
position, while the use of piroxicam and ketoprofen is associated with a higher risk. 
Moreover, clear evidence indicates that a high dose of an NSAID is associated with an 
enhanced risk of ulcer complications in a dose-dependent fashion. (13, 16, 27, 28, 29). 
Moreover, users of multiple NSAIDs are at the highest risk (OR 9.0; 95% confidence interval 
(CI), 5.9±13.6) followed by switchers (OR 6.2; 95% CI, 4.7±8.1) compared with single-NSAID 
users (OR 4.6; 95% CI, 3.9-5.4) (13). 
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Initially, it was suggested that short duration of NSAID therapy may be associated with a 
higher risk of ulcer complications (26,30) perhaps explained by gastric adaptation. However, 
recent cohort studies and meta-analyses indicate that the risk of ulcer complications remains 
constant during NSAID exposure (15,31,32). After discontinuation of NSAIDs the risk of 
ulcer complications declines rapidly, however, being increased during 2 months before 
returning to the base-line level.  
Whether patients are exposed to NSAIDs or not, anticoagulants increase the risk of bleeding 
from pre-existing ulcers because of their antihaemostatic properties. NSAIDs are prescribed 
to anticoagulant users in about 13% of elderly subjects, and the risk of ulcer complications is 
heavily increased (Relative risk (RR)12.7, 95% CI, 6.-25.7; excess risk 2.4%; and NNH1yr~40) 
(33). Anticoagulants alone also increased both the relative and the absolute risk (RR 4.3, 95% 
CI, 2.6-7.2; excess risk 0.68%; NNH1yr ~147). 
One out of seven elderly subjects may use both NSAIDs and corticosteroids (34). Other 
studies (13) have confirrmed the relationship and estimated that the excess relative risk due 
to the interaction between NSAIDs and steroids accounts for almost 60% of all cases using 
both NSAIDs and steroids.  
The use of selective serotonin re-uptake inhibitors (SSRI) seemed to increase the risk of 
upper GI bleeding threefold (OR 3.0; 95% CI, 2.1-4.4) (35). Concomitant use of NSAIDs, 
however, increased the risk substantially, with an OR of 15.6 (95% CI, 6.6±36.6), suggesting 
an important interaction between NSAIDs and SSRI.  
With the discovery of the 2 COX isoenzymes, COX-1and COX-2, it was hypothesized that 
the continuous production of local gastroprotective prostaglandins is mainly COX-1 
dependent, while the inducible production of inflammatory prostaglandins is mainly COX-2 
dependent. Most traditional NSAIDs were found to be nonselective inhibitors of both COX 
isoforms (36). An ideal NSAID would selectively inhibit the inducible COX-2 isoform, 
thereby reducing inflammation and pain, without acting on the constitutive COX-1 isoform, 
thereby minimizing toxicity. On the basis of this hypothesis, several COX-2-selective 
NSAIDs were developed in the 1990s. Celecoxib (Celebrex®), rofecoxib (Vioxx®), and 
valdecoxib (Bextra®) received FDA approval for use in rheumatoid arthritis and 
osteoarthritis, while celecoxib and rofecoxib were also approved for use in acute pain. Two 
other COX-2 selective NSAIDs, etoricoxib (Arcoxia®) and lumircoxib (Prexige®), received 
European approval for use in rheumatoid arthritis, osteoarthritis, and acute gout or 
osteoarthritis, respectively. COX-2-selective NSAIDs demonstrate comparable analgesia and 
anti-inflammatory effects to nonselective NSAIDs in patients with rheumatoid arthritis and 
osteoarthritis (36-40). At their defined therapeutic doses, COX-2-selective NSAIDs show at 
least a 200- to 300-fold selectivity for inhibition of COX-2 over COX-1 (36). Many studies 
have evaluated the efficacy of COX-2-selective NSAIDs on reducing the risk of NSAID 
ulcers. In 2000, 2 pivotal outcome studies, the Celecoxib Long-term Arthritis Safety Study 
(CLASS) and Vioxx Gastrointestinal Outcome Research study (VIGOR), demonstrated that 
COX-2-selective NSAIDs decrease the risk for both endoscopic NSAID ulcers and serious 
NSAID ulcer complications when compared with nonselective NSAIDs (41,42). 
The Multinational Etoricoxib and Diclofenac Arthritis Long-term program was a pooled 
intent-to-treat analysis of 3 randomized comparisons of etoricoxib (60 or 90 mg daily) and 
diclofenac (150 mg daily) in 34,701 rheumatoid arthritis or osteoarthritis patients (43). 
Overall, GI events were significantly less common with etoricoxib than with diclofenac. 
In the Therapeutic Arthritis Research and GI Event Trial, 18,325 osteoarthritis patients were 
randomized to lumiracoxib 400 mg once daily, naproxen 500 mg twice daily, or ibuprofen 
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800 mg 3 times daily for 52 weeks (44). In the patients not taking aspirin, the cumulative 
incidence of serious NSAID ulcer complications (bleeding, perforation, or obstruction) was 
significantly lower with lumiracoxib than with naproxen or ibuprofen (hazard ratio, 0.21; 
95% CI, 0.12 to 0.37). However, there was no significant difference in the patients 
concurrently taking aspirin. Furthermore, there were more myocardial infarctions with 
lumiracoxib, especially as compared with naproxen (0.38% versus 0.21%), although the 
differences were not statistically significant. 
Several tentative conclusions may be drawn from these and other studies. First, the use of 
COX-2-selective NSAIDs significantly reduces the risk of NSAID ulcers and of serious 
NSAID ulcer complications. However, long-term efficacy remains debatable. Second, 
concurrent use of low-dose aspirin for primary or secondary prevention of cardiovascular or 
cerebrovascular disease negates the gastroprotective effect of COX-2-selective NSAIDs. This 
observation may be directly related to effect of aspirin, which irreversibly blocks COX-1 in 
the GI tract (45). Third, the use of COX-2-selective NSAIDs increases the risk of myocardial 
infarction, as compared with the nonselective NSAID naproxen (10). The highly selective 
COX-2 inhibitors such as rofecoxib showed reduced GI side effects but their possible role in 
increasing cardiac adverse effects has resulted in the withdrawal of rofecoxib and 
valdecoxib from the market (1).  
3. Strategies to enhance the safety profile of NSAIDs 
Two strategies have been employed to enhance the safety profile of NSAIDs: the use of 
concomitant medication to protect the gastroduodenal mucosa and the development of safer 
anti-inflammatory drugs: COX-2 selective inhibitors, nitric oxide-donors NSAIDs, 
phospholipid-coupled NSAIDs, N-enatiomers of NSAIDs (12). The other way to enhance the 
safety profile of NSAIDs is to use rectal drug delivery systems or modified release 
formulations. These are less ulcerogenic included methods to reduce topical effects such as 
enteric coating, rectal administration, or sustained relese oral formulations. It is now well 
established that the point prevalence of peptic ulcer disease in patients receiving 
conventional NSAID therapy ranges between 10 and 30%, which is a 10- to 30-fold increase 
over that found in the general population (46). In a study that examined the prevention of 
NSAID-related ulcer complications in 8843 arthritis patients, it was reported that, over a 6-
month trial period, 0.76% of patients (or 1.5% annually) experienced upper GI complications 
(25). The US Food and Drug Administration (FDA) similarly estimates that 2-4% of patients 
taking conventional NSAID for one year experience symptomatic ulcer or potentially life-
threatening ulcer complications (47). The Arthritis, Rheumatism and Aging Medical 
Information Systems (ARAMIS) reported that the overall annual incidence of hospitalization 
for GI events was 1.3%, the rate was 6 times higher in patients with RA who were taking 
NSAID than in those who were not (24). Despite a reduction in the rate of hospitalisation 
(24,48), it has been established that 1 out of 175 users of conventional NSAIDs in the USA 
will be hospitalised each year for NSAID-induced GI damage (49). The mortality of 
hospitalised patients remains about 5-10%, with an expected annual death rate of 0.08% (24).  
4. Suppository formulations 
The advantages of suppositories as conventional formulations compared to other dosage 
forms are reduction of side effects, such as GI irritation and avoidance of disagreable taste, 
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first pass effect, and undesirable effects of meals on drug absorbtion (50-54). There are 
indications for using this route of administration such as when the oral administration of 
medication is difficult due to non-compliance of patient or when GI motility is severely 
impaired. In addition the oral route can not be used in some patients due to oral or 
oesophageal injuries or ulceration and in convulsing neonates rectal administration is easier 
than parenteral or oral administration (55,56). 
After dissolving a suppository containing NSAID in the rectal fluids and absorption by the 
rectal mucosa, the NSAID will be distributed to the various body compartments. The upper 
haemorrhoidal vein will drain the drug into portal system while the middle and lower 
haemorrhoidal veins drain it directly into the inferior vena cava which explains why the 
drug bioavailability may be modified according to the position of the suppository into the 
rectum. At least a part of the drug absorbed will bypass the liver and its first pass 
metabolism (which is of great importance for high clearance drugs but not for low clearance 
drugs such as most of the NSAIDs) will be decreased. It was known that, NSAIDs are 
variably, but usually well absorbed rectally, thereby reducing the risk of GI ulceration and 
NSAID suppositories are one approach, besides many others, that is proposed to limit 
NSAID-induced gastropathy. This proved to be true at least in one study conducted on 45 
normal volunteers who received either indomethacin or placebo suppositories, or oral 
indomethacin. Both suppositories seemed to be better tolerated than oral formulation (57).  
Ersmark H. et al. (58) have used in their study piroxicam and indomethacin suppositories 
for painful coxarthrosis. Six orthopaedic clinics in Sweden made a comparison of the effects 
and side effects of Piroxicam (20 mg) and Indomethacin (100 mg) suppositories in 261 
patients with painful coxarthrosis on the waiting list for total hip replacement. The study 
was designed as a single blind study over 4 weeks. Amount of pain and range of motion 
was registered before the trial and compared with findings after 4 weeks, including reported 
side effects. Both drugs gave satisfactory pain relief without any appreciable variation on 
weightbearing or at rest. On the other hand, the trial showed a significant difference (p = 
0.0033, Student's-test) between the two drugs as regards the frequency of side effects from 
the lower gastrointest GIinal tract, where piroxicam had a lower rate compared with 
indomethacin. No serious complications occurred; 16 patients dropped out, 8 in each group. 
Carrabba M. et al. (59) compared the local tolerability, safety and efficacy of meloxicam 15 
mg suppositories with piroxicam 20 mg suppositories over a 3-week period in a single-
blind, randomized study in patients with osteoarthritis. They found that local adverse 
events occurred in 11.9% of patients receiving piroxicam and 6.9% of those receiving 
meloxicam. Overall, GI adverse events were the most frequent of all 11.9% of piroxicam-
treated patients. In both groups, about 90% of global tolerability assessments were classified, 
by the investigator and the patient, as either very good or good. They concluded that 
meloxicam 15 mg suppositories showed excellent local tolerability accompanied by good 
safety and efficacy in osteoarthritis, which was comparable to that of an established NSAID 
administered by the rectal route, and to that previously observed with oral formulations of 
meloxicam 15 mg.  
Hatori M. et. al (60) used in their study 231 patients aged 16 to 75 years with osteoarthritis of 
the knee joint. Each patient received 20 mg of piroxicam daily as a suppository administered 
before sleep; 75% of the patients were treated for 14 days or longer. Overall treatment 
outcome was excellent in 34% according to physicians' ratings and in 36% according to the 
patients' self-ratings, good in 39% and 41%, fair in 22% and 17%, and unimproved in 5% and 
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7%, respectively. Side effects were reported by 3% of the patients. They concluded that 
treatment of osteoarthritis with piroxicam suppositories is safe and effective.  
Aärynen M. and Palho J. (61) studied with 15 patients having rheumatoid arthritis or 
osteoarthritis. They received a single dose (20 mg) piroxicam (Felden) as suppository. Serum 
piroxicam concentrations were assayed by fluorometry 1, 2, 4, and 8 h after the installation 
of the suppository, the mean values being 1.3, 1.9, 1.8, and 1.8 mg/l, respectively. Then the 
patients continued on oral piroxicam 20 mg daily for maximum 3 weeks, and serum 
piroxicam levels (mean 6.3 mg/l) were checked at the end of this period. Nine patients then 
continued on piroxicam suppositories 20 mg daily for one week, and serum piroxicam levels 
(mean 4.5 mg/l) were again assayed at the end of this maintenance. Pain at rest, pain on 
motion, and joint movement restriction were scored on day 1, after oral maintenance, and 
after rectal maintenance. Reduced scores were found with time, but the only statistically 
significant effect was in the overall subjective pain relief measured after oral maintenance. 
Rectal irritation was recorded in one patient. They concluded that a) absorption of 
piroxicam from suppository was adequate, b) it was possible to maintain adequate serum 
piroxicam levels by repeated administration of suppository for one week, and c) the GI 
toleration was acceptable in these patients selected for showing poor tolerance towards 
other nonsteroidal antiinflammatories.  
In a placebo-controlled double-blind trial analgesic effectiveness and tolerability of alpha-
methyl-4-(2-thienyl-carbonyl)phenylacetic acid (suprofen, Suprol) 300 mg suppositories 
were evaluated for 45 informed patients suffering from chronic pain due to osteoarthritis; 
the subjects were treated rectally, t.i.d., for 10 days. Suprofen proved to be statistically 
significantly superior to placebo in all the variables considered for evaluation of the 
analgesic effect, i.e., pain intensity and relief scores, sum of pain intensity differences, total 
pain relief , global assessments by investigator and patient. In particular, the efficacy of 
suprofen was judged by the physician good or very good in 86.3% of the patients. Similar 
frequencies of rectal side-effects were observed in both treatment groups, with slightly but 
not significantly higher incidence in the group treated with suprofen. Haematologic and 
clinical chemistry laboratory tests showed no statistically significant alterations due to the 
treatment (62). 
Efficacy and toleration of piroxicam suppositories 20 mg, given once daily for 4 weeks were 
assessed in 96 patients suffering from degenerative joint disease and 20 patients suffering 
from rheumatoid arthritis. The mean scores of objective parameters measured (tenderness, 
swelling, limitation of movement) decreased significantly 2 and 4 weeks after initiation of 
therapy. Patients' self-evaluation of pain and stiffness also significantly improved during the 
trial. Overall evaluation of efficacy and toleration were excellent or good in more than 80% 
of patients. Local toleration was excellent in all but two patients (63).  
In a 15 day double-blind clinical trial 39 patients affected with rheumatic disease have been 
enrolled to evaluate the therapeutic effect of rectal administration of Piroxicam, in 
comparison with Indomethacin. At the end of the study, 20 patients had been treated with 
Piroxicam and 19 with Indomethacin. Nine patients in the Indomethacin group and one in 
the Piroxicam group dropped-out. Both drugs safety resulted good in the patients who 
completed the study, whereas 5 out of 10 dropped-out patients stopped the trial in 
consequence of severe side-effects of Indomethacin. Piroxicam induced a very good 
improvement in 76% of the patients, moderate in 19% and no improvement in 5%; 
Indomethacin induced a very good improvement in 75% of the patients, moderate in 15% 
and no improvement in 10%. No significative modifications resulted from the control of the 
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laboratory blood tests. Piroxicam (30 mg/die) showed a therapeutic activity similar to 
Indomethacin (100 mg/die). The rectal administration of Piroxicam can be then considered a 
very good alternative to the oral one, particularly in the patients in which oral use of NSAID 
is counter-indicated (64). 
Ketoprofen administered via the rectal route seemed to be valuable when given at night to 
patients with various rheumatic syndromes and may be particularly useful for patients who 
show gastric intolerance of the capsules. Anal intolerance was noted in 12% of the patients 
(65).  
The relative risks associated with anti-inflammatory drug prescription for patients with an 
earlier history of drug-associated gastro-intestinal disturbance have been investigated by 
Bunton RW. et. al (66) in a retrospective study. Under these circumstances ibuprofen was 
well tolerated. The risks associated with modified salicylates (principally aspirin in enteric-
coated form) and indomethacin suppositories also appeared to be relatively slight.  
Together with NSAIDs a lot of other drugs such as alendronate sodium (ALD) have GI side 
effects. ALD is a bisphosphonate medication used in the treatment and prevention of 
osteoporosis. Absorption of ALD as oral formulation is very poor (0.5-1%). Its bioavailability 
can decrease with food effect. It has some GI adverse effects such as gastritis, gastric ulcer, 
and esophagitis. Asikoglo et al. (67) developed in their study a rectal formulation of ALD as 
an alternative to oral route and investigated the absorption of it by using gamma 
scintigraphy. For this reason, ALD was labelled with Technetium-99m (99mTc) by direct 
method. They found that the rectal absorption of 99mTc-ALD from suppository formulation 
was possible. According to their results, this formulation of ALD can be suggested for the 
therapy of osteoporosis as an alternative route. Asikoglu et al. (68) developed in another 
study a vaginal suppository formulation of ALD and they showed that the vaginal 
absorption of 99mTc-ALD from suppository formulation was also possible.  
It was known that sustained release (SR) suppositories together with suppositories are other 
important formulations to reduce the GI side effects. In the case of drugs that are rapidly 
eliminated from the systemic circulation, frequent administration would be needed to 
maintain the therapeutic plasma concentration. To reduce the frequency of dosing, several 
approaches have been performed to prepare SR suppositories by using various polymer 
such as chitosan (69), Eudragit (70-72), cellulose acetate phthalate (73), carboxyvinyl 
polymer (74), and various hydrogel formulation (75,76), were also investigated. Özgüney et. 
al. (77) prepared SR suppositories of ketoprofen (KP). Since KP produces gastro-intestinal 
side effects and its administration rectally is considered as a serious alternative to the oral 
route (75). KP is an appropriate model drug for formulation of controlled release dosage 
forms due to its short plasma elimination half-life and poor solubility in unionized water, 
which affects its bioavailability (78). They designed KP SR suppositories according to the 
32x21 factorial design as three different KP:Eudragit RL 100 ratios, three particle sizes of 
prepared granules and two different PEG 400:PEG 6000 ratios. The conventional KP 
suppositories also prepared with Witepsol H 15, Massa Estarinum B, Cremao and the 
mixture of PEG 400:PEG 6000. The dissolution studies of suppositories prepared was carried 
out according to the USP XXIII basket method and it was shown that the dissolution time 
was sustained to 8 hours. In addition, they determined antiinflammatory activity of SR 
suppository as significantly extended according to the conventional suppositories.  
Güneri et. al. (79) reported that formulation of sustained-release suppositories using 
ibuprofen-ethylcellulose microspheres was attempted. Ibuprofen was an appropriate 
candidate for sustained-release formulation because of its short half-life (1.8-2 hrs) and 
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undesired GI effects when it is administrated through oral route, such as peptic ulceration 
and GI bleeding.  
There are a lot of studies on SR suppositories prepared with NSAIDs to reduce their GI side 
effects (80,81).  
Liquid suppository formulations are newer SR suppository formulations according to the 
conventional suppository formulations. Conventional suppositories are solid forms which 
often cause discomfort during insertion. The leakage of suppositories from the rectum also 
gives uncomfortable feelings to the patients. In addition, when the solid suppositories 
without mucoadhesivity reach the end of the colon, the drugs can undergo the first-pass 
effect. To solve these problems, Choi et.al. (82) developed a novel in situ-gelling and 
mucoadhesive acetaminophen liquid suppository with gelation temperature at 30–36°C and 
suitable gel strength and bioadhesive force. Poloxamer 407 (P407) or/and poloxamer 188 
(P188) were used to confer the temperature-sensitive gelation property.The mixtures of P407 
(15%) and P188 (15–20%) existed as a liquid at room temperature, but gelled at 30–36°C. 
They studied bioadhesive polymers such as polyvinylpyrrolidone, 
hydroxypropylmethylcellulose, hydroxypropylcellulose, carbopol and polycarbophil to 
modulate the gel strength and the bioadhesive force of acetaminophen liquid suppositories. 
Choi et. al. (83) showed in their another study that liquid suppository A [P 407:P 
188:polycarbophil:acetaminophen (15:19:0.8:2.5%)], which was strongly gelled and 
mucoadhesive in the rectum, showed more sustained acetaminophen release profile than 
did other suppositories and gave the most prolonged plasma levels of acetaminophen in 
vivo. Liquid suppository A also showed higher bioavailibility of acetaminophen than did 
the conventional formulation and it did not cause any morphological damage to the rectal 
tissues.  
Özguney et. al. (84, 85) prepared a liquid suppository formulation using P407, P188, 
ketoprofen and various amounts of different bioadhesive polymers (PVP, CMC, HPMC and 
Carbopol 934 P). Because of the gastro-intestinal side effects ketoprofen was choosen as 
active ingredient. They investigated the release and mechanical characteristics of the 
formulations . As to the obtained results of in vitro drug release studies, Carbopol has the 
bigest effect on release rate among the bioadhesive polymers. It was seen that the release 
rate decreased with increasing of Carbopol cocentration. The release rate decreased between 
the formulations having highest or lowest concentrations of Carbopol in percent of 20 at 8. 
hour.  
5. Enteric-coated formulations 
Enteric-coated (EC) products are designed to minimize exposure of a drug to the acidic pH 
in the stomach, which could result in its degradation, or to decrease gastric side effects such 
as ulcers, perforations and bleeding due to the local effects of the drug on the gastric 
mucosa. Cellulose acetate phthalate is the polymer most commonly use for enteric coating. 
The core in such a formulation is coated with this polymer, which does not dissolve at a 
gastric pH. The dissolution of coating begins at a higher intestinal pH (generally at a pH 
higher than 5) as the tablet transist out of stomach into the intestine. Generally, the enteric-
coated products are tablets. However, small beads or spheroids can be covered with an 
enteric coating and than these beads can be placed in a hard gelatin capsule (86). 
Ethylcellulose and cellulose acetate phthalate capsules in the form of Snap-Fit type hard 
gelatin capsules were developed for controlled release and enteric-coated dosage forms 
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respectively. The capsules were drilled in different diameters by using laser and filled with 
concentrated drug solution. In vitro and in vivo drug releases were investigated (87). In an 
another study, the enteric-coated capsules were prepared using hydroxypropylmethyl 
cellulose phthalate and examined in vitro and in vivo drug releases (88,89).  
Although diclofenac sodium (DFNa), is a conventional NSAID, it could be fully utilized 
without harmful side effects if it was properly formulated (90). When it comes to oral 
administration of DFNa, at least two requirements should be considered: (a) perfect drug 
retention under gastric conditions, and (b) sufficient drug release during intestinal residence 
time. To achieve these requirements, a variety of controlled release formulations for DFNa 
have already been reported. In terms of pH-responsive matrices, water-soluble matrix 
tablets containing DFNa coated with hydroxypropyl methylcellulose phthalate (HPMCP) 
for delayed release of DFNa (91) and DFNa-loaded pH-sensitive microspheres comprising 
of poly(vinyl alcohol) and poly(acrylic acid) interpenetrating network for the delivery of 
DFNa to intestines were prepared and evaluated in vitro (92). Novel enteric microcapsules 
were reported, and in vivo evaluation of dosage forms showed successful 
pharmacodynamic activities (93). 
Due to the necessity to pass intact through the stomach for reaching the duodenum for 
absorption, the pantoprazole is formulated as solution for intravenous administration 
(lyophilized powder for reconstitution) or as gastric-resistant tablets (oral delayed-release 
dosage form). In the case of oral administration, the enteric coating prevents pantoprazole 
from degradation in the gastric juice (at pH 1–2, pantoprazole degrades in few minutes) (94). 
As a general rule, the multiple-unit products show large and uniform distribution; they are 
less affected by pH and there is a minor risk of dose dumping (95). Besides, these new drug 
delivery systems, as the polymeric microparticles, are also proposed to improve absorption, 
distribution, and bioavailability of acid labile drugs (96,97). As they rapidly disperse in the 
GI tract, they can maximize drug absorption, minimize side effects, and reduce variations in 
gastric emptying rates and intersubject variability (98,99).  
Caldwell J.R. et al. (100) compared in their study efficacy and GI tolerability of a new enteric 
coated formulation of naproxen (NAP-EC) with standard immediate release naproxen 
(NAP-STD). For this reason one hundred seventy-nine patients with osteoarthritis and one 
hundred seventy-six patients with rheumatoid arthritis at high risk for developing GI side 
effects to NSAID therapy were enrolled in a double blind, parallel, multicenter study. All 
patients had either discontinued as NSAID during the previous one year or required 
cotreatment with antiulcer drugs for control of GI complaints related to NSAID use. The 
treatments were evenly divided in both diagnostic cohorts. As to the obtained results of 
their study, except for minor differences in alcohol consumption, baseline characteristics of 
patients in both treatment groups were statistically similar. Both naproxen formulations 
were highly efficacious by all variables of disease activity when changes were measured 
from baseline. No statistically significant between formulation difference was found in the 
primary efficacy variable, overall disease activity. Overall, between formulation differences 
in efficacy measures were few, though most favored NAP-STD. GI complaints were reduced 
by 15% (51% NAP-EC vs 60% NAP-STD, p = 0.077) and GI complaints thought to be drug 
related were reduced by 36% (16% NAP-EC vs 25% NAP-STD, p = 0.024). Withdrawals due 
to GI complaints were reduced by 37% in the NAP-EC group (12% NAP-EC vs 19% NAP-
STD, p = 0.054), and withdrawals due to GI complaints judged to be drug related were 
reduced by 55% in the NAP-EC group (6% NAP-EC vs 12% NAP-STD, p = 0.025). They 
concluded that enteric coated naproxen is an effective treatment for osteoarthritis and 
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rheumatoid arthritis. All observed differences in GI tolerability favor NAP-EC over NAP-
STD.  
The damaging effect of enteric-coated and plain naproxen tablets on the gastric mucosa was 
studied in 12 healthy subjects before and after 7 days' treatment in a randomized, double-
blind, double-dummy, cross-over trial. Both formulations of the drug caused mucosal 
lesions, but the extent of the damage was significantly decreased after enteric-coated 
naproxen as compared with plain tablets. The subjects' preference was significantly in 
favour of the enteric-coated naproxen tablets. The plasma naproxen concentration was 
significantly higher after treatment with enteric-coated naproxen than after treatment with 
plain tablets. In conclusion, the results of the study indicate that naproxen might damage 
the gastric mucosa by local and systemic effects and that the local effect might be prevented 
by enteric coating of the tablets (101).  
Aabakken L. et al. (102) studied the GI side effects of three formulations of naproxen in 18 
healthy male volunteers. In a Latin-square design crossover study, the subjects received 500 
mg naproxen twice daily for 7 days as plain tablets, enteric-coated tablets, or enteric-coated 
granules in capsules. The 51Cr-EDTA absorption test was performed before and at the end 
of each drug period, to evaluate changes in the distal gut. The test dose was instilled distally 
in the duodenum to prevent lesions in the stomach from interfering with the evaluation. 
Upper endoscopy was performed at the same intervals, scoring changes in the middle and 
distal duodenum separately from findings in the stomach and duodenal bulb. The nature 
and severity of adverse effects were recorded for each treatment period. Non-parametric 
methods were used for statistical evaluation. All drugs induced a significant increase in 
51Cr-EDTA absorption, but they did not detect any difference between the three 
formulations. All formulations were associated with a significant increase in all the 
endoscopic findings monitored. Enteric-coated tablets induced significantly less lesions than 
enteric-coated granules in the stomach and duodenal bulb, and an advantage over plain 
tablets was indicated. No difference was seen in the middle and distal duodenum. The 
proximal endoscopic scores were not correlated to those found in the middle and distal 
duodenum. Evaluation of the small and large bowel should probably be included in clinical 
studies of NSAIDs, but their findings suggest that the importance of transfer of mucosal 
lesions to the distal gut by enteric coating may have been overemphasized.  
The effects of plain and enteric-coated fenoprofen calcium (Nalfon, Dista, Indianapolis, Ind.) 
on GI microbleeding were studied in 32 normal male volunteers in a randomized, open-label, 
parallel trial at two inpatient research facilities. A 1-week placebo (baseline) period preceded 2 
weeks of fenoprofen therapy (enteric coated or plain, 600 mg q.i.d.). Fecal blood loss was 
measured by 51Cr-tagged erythrocyte assay and averaged over days 4 to 7 (baseline) and 11 to 
14 and 18 to 21 (active therapy). At one center GI irritation was evaluated endoscopically 
before and after active therapy. Endoscopy showed both formulations to cause mucosal 
damage not evident by subject-reported symptoms. Four of the 16 subjects developed 
asymptomatic duodenal ulcers. Mean daily fecal blood loss was significantly lower (P = 0.03) 
with enteric-coated (mean +/- SD, 1.104 +/- 0.961 ml/day) than with plain fenoprofen calcium 
(mean +/- SD, 1.686 +/- 0.858 ml/day), suggesting that tolerance of fenoprofen can be 
improved with administration in an enteric-coated form (103).  
When administered on a chronic high-dosage regimen, enteric-coated aspirin granules 
produced significantly less gastric damage than plain aspirin or aspirin-antacid 
combinations. Clinically meaningful damage occurred in all subjects receiving plain aspirin, 
93% of those receiving aspirin-antacid combination and only 27% and 20% of those 
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receiving enteric-coated aspirin granules qid and bid, respectively. All three aspirin 
formulations were taken as 1 g qid (4 g/day) and an additional group received enteric 
granules administered as 2 g bid (4 g/day). Gastric damage was assessed by means of 
endoscopy carried out after seven days of treatment. Enteric granules are equally safe when 
administered on a bid or qid regimen (at same total daily dosage) and, in a bid regimen, 
should provide a compliance advantage for patients on high-dose therapy for diseases such 
as rheumatoid arthritis (104).  
6. Sustained and controlled release formulations 
The development of oral sustained and controlled release formulations offers some benefits: 
controlled administration of a therapeutic dose at the desired delivery rate, constant blood 
levels of the drug, reduction of side effects, minimization of dosing frequency and 
enhancement of patient compliance (105).  
The basic rationale for the development of controlled drug delivery is to modulate the 
magnitude and duration of drug action(s), and to dissociate it from the inherent properties 
of the drug molecule. To enable optimal design of controlled release systems, a thorough 
understanding of the pharmacokinetics and pharmacodynamics of the drug is necessary. 
In many cases, the development of SR dosage forms is somewhat empirical. It is often based 
on the sole objective of reducing the dosing frequency or fluctuation between peak and 
trough plasma concentrations (C and Cmax respectively) associated with conventional 
tablet or capsule formulations. The development process tends to be based on an intuitive 
pharmacodynamic rationale assuming that the magnitude of response elicited by the drug is 
closely related to changes in its plasma concentration (106). 
In general, almost all drugs cause side effects or have extraneous activity in addition to their 
primary therapeutic function. An important principle in the design of a proper delivery 
system for a drug is the conconsideration that each of the pharmacologic effects of the drug 
has its own pharmacodynamic profile. Furthermore, while a certain pharmacological effect 
is considered as a therapeutic response, 
larger intensities of the same effect are regarded as undesired (and possibly toxic). Thus, an 
important advantage of SR formulations is that by narrowing the range of drug 
concentrations (especially, by reducing Cmax levels) the delivery system enables the 
minimization of the adverse effects associated with elevated drug concentrations. This 
pharmacodynamic principle has been widely applied as a means to improve drug therapy 
(107). There are numerous examples to demonstrate modulation of adverse effect of NSAIDs 
by SR formulations (108-115).  
Lipid-based formulations have attracted increasing attention for improvement of 
bioavailability of hydrophobic drugs in comparison with solid dosage forms (116). In fact, 
lipid microspheres composed of lecithin and soybean oil were tested as carriers for 
hydrophobic NSAIDs (117). Unlike many of NSAIDs, DFNa is basically watersoluble at 
neutral pH, making it difficult to exist in an oil-based formulation. Although self-
emulsifying drug delivery system (SEDDS) composed of goat fat and Tween 65 was also 
applied to diclofenac (90).  
Twenty-five inpatients with chronic inflammatory rheumatic disease were entered into a 
double blind crossover trial. Consecutive treatment regimens consisted of a single daily 
dose of Bi-Profenid 150 mg at 8 pm for 3 days and a single placebo tablet at 8 pm for 3 days. 
Order of treatment regimens was randomly assigned. Bi-Profenid proved highly superior to 
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placebo with a very significant (p less than 0.01) difference in effectiveness on nocturnal 
pain, morning stiffness and pain evaluated on the pain scale. During the short treatment 
period no significant clinical side-effects were recorded. The authors conclude that Bi-
Profenid is effective at a daily dosage of 150 mg, thus enabling to adjust prescriptions to 
actual needs when pain is not continuous throughout the 24 hours (118). 
Schumacher HR. et al. (119) described a new extended-release formulation that maintains 
therapeutic plasma ketoprofen concentrations for up to 24 hours. A single 200-mg capsule 
thus provides daytime and nighttime symptom control. Small pellets, enclosed in a gelatin 
capsule, are released in the stomach but release their contained ketoprofen only after 
reaching the nonacidic environment of the small intestine. Diurnal fluctuations in plasma 
concentrations of ketoprofen are reduced, and the drug does not accumulate in plasma with 
extended use. The half-life of the drug from this dosage form is not significantly affected by 
the increasing age of the patients. The efficacy of extended-release ketoprofen in British 
clinical trials has been comparable to that of conventional ketoprofen or naproxen. Safety 
profiles have been comparable to profiles of other NSAIDs; adverse effects have usually 
been mild and transient, although, as with other NSAIDs, ulcers and bleeding can occur. 
Extended-release ketoprofen appears to be a good choice for the symptomatic treatment of 
rheumatoid arthritis and osteoarthritis. Convenient once-daily administration may help 
improve patients' compliance.  
An open study was carried out in 46 patients with osteoarthritis of the hip to compare the 
efficacy and tolerance of treatment with ketoprofen given either as 100 mg capsules twice 
daily or as 2 capsules of 100 mg ketoprofen in a controlled-release formulation given once 
daily. The results of subjective and objective assessments before and during 3-months' 
treatment in the 48 patients who completed the trial showed both treatments produced 
improvement in all parameters, except for the time taken for inactivity stiffness to develop, 
and there was no significant difference between treatments in terms of efficacy. The 
controlled-release preparation, however, was significantly better tolerated than the ordinary 
capsule form. Minor haematological and biochemical changes during treatment were noted 
but these were not of clinical importance. Six patients, 2 receiving the controlled-release and 
4 receiving the ordinary formulation of ketoprofen, were withdrawn because of lack of 
efficacy or unacceptable side-effects (120).  
A multi-centre, double-blind, crossover study was carried out in 80 patients with 
rheumatoid arthritis to compare the efficacy and side-effect profiles of two formulations of 
indomethacin. Patients were allocated at random to receive 75 mg indomethacin per day 
either as 1 controlled-release tablet at night or as 1 immediate-release capsule given 3-times 
a day for a period of 4 weeks before being crossed over to receive the alternative treatment 
for a further 4 weeks. Pain scores, daily symptomatology and the requirement for escape 
analgesia recorded by both investigator and patient indicated that controlled-release 
indomethacin tablets, 75 mg given at night, was as efficacous as immediate-release 
indomethacin capsules given 3-times daily. However, the controlled-release formulation 
had a superior side-effect profile with a reduced incidence of abdominal/epigastric pain 
compared to the immediate-release preparation (121). 
Prichard PJ. et al. (122) have compared acute gastric bleeding caused by a new slow release 
preparation of indomethacin (indomethacin Continus) with that caused by aspirin and other 
indomethacin preparations. In a randomized crossover study, blood loss into timed gastric 
aspirates was determined in 20 healthy volunteers after receiving, over 96 h, either placebo, 
aspirin (600 mg four times daily; 17 doses) indomethacin BP (50 mg three times daily; 13 
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doses), Indocid-R (75 mg twice daily; 9 doses) or indomethacin Continus (75 mg twice daily; 
9 doses). A venous blood sample was also taken during each treatment period for 
subsequent determination of alpha 1-glycoprotein, and for drug assay. Gastric bleeding on 
placebo was 1.4 (0.7-2.8) microliters 10 min-1 (mean, 95% CI). Both aspirin and the 
indomethacin preparations caused significantly more bleeding (P less than 0.05). Rates of 
bleeding after aspirin, indomethacin BP, Indocid-R, and indomethacin Continus were 
respectively 22.0 (10.7-47.2) microliters 10 min-1, 4.4 (2.2-9.1) microliters 10 min-1, 10.8 (5.3-
22.3) microliters 10 min-1, and 5.1 (3.0-10.6) microliters 10 min-1. 4. Rates of bleeding after 
indomethacin BP and indomethacin Continus, but not Indocid-R, were significantly less 
than after aspirin (P less than 0.01). Salicylate or indomethacin was detectable in the plasma 
of all subjects after the active treatment periods, except for one instance involving a subject 
allocated indomethacin BP. Indomethacin levels were significantly higher 2 h after Indocid-
R than with indomethacin BP or indomethacin Continus. 6. alpha 1-acid glycoprotein levels 
were not significantly affected by prior treatment with aspirin or indomethacin. 
GI blood loss was measured in 30 healthy male volunteers before and during 4 weeks of oral 
treatment with either tiaprofenic acid tablets 300 mg twice daily, tiaprofenic acid sustained 
action (SA) capsules 600 mg once daily, or indomethacin SR capsules 75 mg once daily, in an 
open parallel-group study of 38 days' duration. Autologous erythrocytes labelled with 51Cr 
were given intravenously on the first study day. GI blood loss was measured by comparing 
faecal and red blood cell 51Cr activity during the second and fourth weeks of drug 
treatment. Blood loss was significantly greater during treatment with all 3 active 
preparations than during the pretreatment period, but this comparison is of limited value 
because placebo was not given in parallel and because in 4 subjects, who had to have their 
erythrocytes relabelled, there was no pretreatment data. The tiaprofenic acid SA group had 
consistently lower blood loss than the tiaprofenic acid tablet group. Both these groups also 
had consistently lower blood loss than the indomethacin SR group, although the difference 
between the treatment groups was not significant. Blood loss during the fourth week of 
treatment was less than during the second week of treatment for both the tiaprofenic acid 
SA and indomethacin SR capsule groups. With tiaprofenic acid tablets, blood loss was very 
similar at weeks 2 and 4 but this result should be viewed with caution because data at week 
2 were missing for 3 subjects. Thus, formulation of tiaprofenic acid as a sustained action 
capsule does not appear to increase gastric irritancy as measured by faecal blood loss (123).  
Fourty adult patients with coxarthrosis were treated for 30 days with oral diclofenac sodium 
at the daily dose of 150 mg: 20 of these were administered one 150 mg prolonged-release 
capsule per day, the other 20 received one 50 mg enteric-coated tablet every 8 hours. The 
presence and severity of several symptoms and signs (various pain types, cramps, morning 
stiffness, impaired function capacity), the intensity of pain through the Visual Analogical 
Scale and some laboratory tests (Erythrocyte Sedimentation Rate, C-reactive protein, 
Rheuma test) were controlled to monitor drug efficacy. The routine laboratory tests of blood, 
liver and kidney function, the GI tolerance of the two administered formulations and the 
appearance of any adverse event were controlled to monitor drug tolerability. Both 
administration schemes yielded very positive results as to treatment efficacy, although the 
prolonged-release capsule often induced a somewhat quicker response. At the end of the 
one-month treatment more than half of patients in both groups registered disappearance of 
several symptoms and a noticeable reduction of the remainder ones. Systemic tolerability 
was also good, with superimposable results in the two groups; GI tolerance on the contrary 
was better in the recipients of the prolonged-release capsules (2 cases of dyspepsia) with 
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respect to those treated with the enteric-coated tablets (2 cases of gastric pyrosis and 2 cases 
of gastralgia). No adverse events were registered (124).  
A double-blind, double-dummy, crossover study was carried out in 8 centres to compare the 
efficacy and tolerability of 'controlled-release' ketoprofen tablets (200 mg) with that of 
indomethacin suppositories (100 mg) in out-patients with definite or classical rheumatoid 
arthritis. Patients were allocated at random to receive a daily bedtime dose of either 1 
ketoprofen tablet or 1 indomethacin suppository plus the dummy of the other formulation 
for a period of 3 weeks. They were then crossed over to the alternative treatment for a 
further 3 weeks. Daily diary records were kept by patients of the number of night-time 
awakenings due to pain, pain severity at awakening in the morning and the duration of 
early morning stiffness. Treatment efficacy was also assessed at the end of each trial period 
by means of an articular index and by physician's and patient's overall evaluation of 
response. Adverse effects spontaneously mentioned by the patients or elicited by direct 
questioning using a symptom check-list were recorded. Statistical analysis of the results 
from 83 evaluable patients showed that the 'controlled-release' tablet formulation of 200 mg 
ketoprofen was equally as effective as the 100 mg indomethacin suppository in the 
treatment of rheumatoid arthritis, especially with regard to pain at awakening and morning 
stiffness. Side-effects in both groups were those commonly seen with non-steroidal anti-
inflammatory drugs and, as expected, GI and CNS disturbances predominated. Overall, 
side-effects were fewer with ketoprofen than with indomethacin (125).  
There are several histological studies which showes that controlled release formulations of 
NSAIDs are alternatives for preventing of gastric lesions. 
Nishihata T. et al. (126) showed in their study that the increased solubility of sodium 
diclofenac in a suppository base in the presence of lecithin resulted in a slow release of 
sodium diclofenac from the base. Rat rectal mucosal damage caused by sodium diclofenac 
was moderated by the administration of the lecithin suppository, probably due to the low 
concentration of sodium diclofenac in the rectal fluid due to a slow release of sodium 
diclofenac from the lecithin suppository. 
A mefenamic acid-alginate bead formulation (127, 128) and mefenamic acid spherical 
agglomerates (129) prepared with various polymethacrylates were developed in different 
studies and evaluated histologically. Histological studies showed that the administration of 
mefenamic acid in alginate beads or spherical agglomerates prevented the gastric lesions. 
Another work reports on a new pharmaceutical formulation for oral delivery of diclofenac 
sodium (DFNa). Although DFNa itself is water-soluble at neutral pH, it was readily 
suspended in soybean oil via complex formation with an edible lipophilic surfactant and a 
matrix protein. The resulting solid-in-oil (S/O) suspension containing stably encapsulated 
DFNa in an oil phase markedly reduced the risks for GI ulcers upon oral administration 
even at the LD50 level in rats (ca. 50 mg/kg DFNa) (90).  
7. H. pylori induced gastric ulcers 
H. pylori is a gram-negative microaerophilic non-invasive spiral bacillus which has the 
ability to colonize the gastric mucosa (130). It causes indolent but chronic inflammation in 
the gastric mucosa and its clinical course is highly variable (131). It has a powerful urease 
enzyme which catalyses hydrolysis of urea to ammonia, enabling the bacteria to survive in 
the acid milieu. Although it induces a strong host local and systemic immune response 
(which is important in pathogenesis) it has also developed mechanisms to evade host 
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immunity. This means that following initial infection, which usually occurs in childhood, it 
is able to persist lifelong in the absence of effective treatment. This persistent infection and 
inflammation underlies disease, which usually occurs in adults. Worldwide, H. pylori 
colonizes >50% of the population and is by far the most important cause of peptic ulcers and 
gastric adeno-carcinoma. Its prevalence varies from more than 80% in developing countries 
to less than 20% in some developed countries, where it is steadily falling due to improved 
hygiene and sanitation, and possibly increased antibiotic use. 
Only about 15% of individuals infected with H. pylori develop a peptic ulcer: who develops 
disease depends on bacterial, host and environmental factors (130). The infection is usually 
limited to the antrum, resulting in hypersecretion of acid and the development of duodenal 
ulcers, which is basically an acid injury. However, the infection sometimes spreads 
proximally, causing diffuse inflammatory damage to the gastric mucosa in the body of the 
stomach and resulting in a gastric ulcer. The inflammation induced by H. Pylori damages 
the natural defence of the gastric mucosa (131).  
The risk of ulceration is higher with more virulent strains. The best-described virulence 
determinants are expression of active forms of a vacuolating cytotoxin (VacA) (132) and 
possession of a protein secretory apparatus called Cag (cytoxin-associated gene products) 
that stimulates the host inflammatory response (133). Cag+ strains interact more closely 
with epithelial cells and induce release of pro-inflammatory cytokines, thereby increasing 
inflammation. Host genetic susceptibility and environmental factors may affect the risk; for 
example, smoking is strongly associated with peptic ulceration in H. pylori-infected 
individuals (134). H. pylori-induced duodenal ulceration arises in people with antral-
predominant gastritis (135). Gastric ulceration occurs on a background of pangastritis, often 
arising at the highly inflamed transitional zone between antrum and pylorus, particularly on 
the lesser curve. Identical hormonal changes occur, but acid production from the inflamed 
corpus is reduced or normal. 
H. pylori appears to be responsible for 95% of the cases of gastritis and 65% of gastric ulcers 
(136). Although most individuals with H. pylori are asymptomatic, there is now convincing 
evidence that this bacterium is the major etiologic factor in chronic dyspepsia, H. pylori-
positive duodenal and gastric ulcers and gastric malignancy (137, 138). Consequently, H. 
pylori eradication is now recognized to be the correct approach along with conventional 
therapies in the treatment of the disease. Options that have been considered to treat peptic 
ulcer disease include taking drugs such as antacids, H -blockers, antimuscarinics, proton 
pump inhibitors and combination therapy for gastritis associated with H. pylori. The 
eradication of H. pylori is limited by its principle unique characteristics. Once acquired, it 
penetrates the gastric mucus layer and fixes itself to various phospholipids and glycolipids 
on the epithelial surface, including phosphatidylethanolamine (139), GM3 ganglioside (140) 
and Lews antigen (141). For effective H. pylori eradication, therapeutic agents have to 
penetrate the gastric mucus layer to disrupt and inhibit the mechanism of colonization. This 
requires targeted drug delivery within the stomach environment. Although most antibiotics 
have very low in-vitro minimum inhibitory concentrations against H. Pylori, no single 
antibiotics has been able to eradicate this organism effectively. Currently, a drug 
combination namely ‘‘triple therapy’’ with bismuth salt, metronidazole and either 
tetracycline or amoxycillin with healing rates of up to 94% has been successfully used (142-
144). The principle of triple therapy is to attack H. pylori luminally as well as systemically. 
The current treatment is based on frequent administration (4 times daily) of individual 
dosage forms of bismuth, tetracycline and metronidazole (Helidac Therapy, consisting of 
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262.4 mg bismuth subsalicylate, 500 mg tetracycline and 250 mg metronidazole). The 
associated limitations are the complex dosing regimen/frequency, large amount of dosage 
forms and reduced patient compliance. Therefore, a successful therapy not only includes the 
selection of the right drugs but also the timing and frequency as well as the formulation of 
the delivery system (2).  
8. Dosage forms with prolonged gastric residence time 
More than 50% of the pharmaceutical preparations on the market are for oral 
administration. The advantages of this route include the ease of administration, and 
avoidance of the pain and discomfort associated with injections. However, for drugs whose 
target is the stomach, such as antibiotics against H.pylori for local treatment of gastric ulcer, 
the development of oral drug delivery systems meets with physiological obstacles such as 
limited residence time and inefficient drug uptake by the gastric mucosa (145). Long-term 
monotherapy of gastric ulcer patients with amoxycillin is ineffective even at high daily 
doses, apparently due to limited contact time with the target site when administered in a 
conventional oral dosage form (138, 146-148). 
The degredation of antibiotics in gastric acid may be the other reason of ineffectiveness 
(149). Local diffusion of the drug in the mucosa appears to be essential for achieving 
bactericidal levels in both healthy subjects (138) and patients: for example, more complete 
eradication of H. pylori was achieved by applying a new method of topical therapy in which 
an amoxycillin solution was kept in contact with the stomach for 1 h (150). The development 
of oral amoxycillin dosage forms with prolonged gastric residence time is therefore an 
attractive goal. Several strategies have been developed in order to prolong the gastric 
residence time of dosage forms and target the gastric mucosa, including the use of floating, 
floating in situ gelling, swelling, expanding and bioadhesive forms (151-156). A new 
strategy is proposed for the triple drug treatment (tetracycline, metronidazole and bismuth 
salt) of Helicobacter pylori associated peptic ulcers. The design of the delivery system was 
based on the swellable asymmetric triple layer tablet approach, with floating feature in 
order to prolong the gastric retention time of the delivery system. Tetracycline and 
metronidazole were incorporated into the core layer of the triple-layer matrix for controlled 
delivery, while bismuth salt could be included in one of the outer layers for instant release. 
Results demonstrated that sustained delivery of tetracycline and metronidazole over 6–8 h 
can be easily achieved while the tablet remained afloat. The floating aspect was envisaged to 
extend the gastric retention time of the designed system to maintain effective localized 
concentration of tetracycline and metronidazole. The developed delivery system has 
potential to increase the efficacy of the therapy and improve patient compliance (2). 
Floating in situ gelling system of clarithromycin (FIGC) was prepared using gellan as gelling 
polymer and calcium carbonate as floating agent for potentially treating gastric ulcers, 
associated with H.pylori. The in vivo H. pylori clearance efficacy of prepared FIGC and 
clarithromycin suspension following oral administration, to H. pylori infected Mongolian 
gerbils was examined by polymerase chain reaction (PCR) technique and by a microbial 
culture method. FIGC showed a significant anti-H. pylori effect than that of clarithromycin 
suspension. It was concluded that prolonged GI residence time and enhanced 
clarithromycin stability resulting from the floating in situ gel of clarithromycin might 
contribute better for complete clearance of H. Pylori (157). Rajinikanth P.S et al. (149) 
developed in their another study a intra-gastric floating in situ gelling system for controlled 
delivery of amoxicillin for the treatment of peptic ulcer disease caused by H.pylori. They 
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prepared gellan based amoxicillin floating in situ gelling systems (AFIG). The in vivo H. 
pylori clearance efficacy of the formulation was examined by the same technique . It showed 
a significant anti-H. pylori effect in the in vivo gerbil model. It was noted that the required 
amount of amoxicillin for eradication of H. pylori was 10 times less in AFIG than from the 
corresponding amoxicillin suspension. The results further substantiated that the prepared 
AFIG has feasibility of forming rigid gels in the gastric environment and eradicated H. 
pylori from the GI tract more effectively than amoxicillin suspension because of the 
prolonged GI residence time of the formulation.  
A gastroretentive drug delivery system of DA-6034, a new synthetic flavonoid derivative, 
for the treatment of gastritis was developed by using effervescent floating matrix system 
(EFMS). The therapeutic limitations ofDA-6034 caused by its low solubility in acidic 
conditions were overcome by using the EFMS, which was designed to cause tablets to float 
in gastric fluid and release the drug continuously. The release of DA-6034 from tablets in 
acidic media was significantly improved by using EFMS, which is attributed to the effect of 
the solubilizers and the alkalizing agent such as sodium bicarbonate used as gas generating 
agent. DA-6034 EFMS tablets showed enhanced gastroprotective effects in gastric ulcer-
induced beagle dogs, indicating the therapeutic potential of EFMS tablets for the treatment 
of gastritis (158). 
In another example, it was found that in normal volunteers ionexchange resins achieved 
excellent distribution in the gastric cavity and had a prolonged gastric residence time, 20-
25% remaining for 5.5 h. (155). More recent results by the same group indicate that the 
mechanism by which resin particles adhere to the mucosa is unlikely to be chargebased, 
since they persist in the stomach regardless of whether they bear a non-adhesive polymer 
coating and regardless of whether the stomach contains food (156). Other authors have 
recently shown that ion-exchange resins also interact with other mucosal surfaces, such as 
the nasal mucosa (159). Because of this reason, microparticles consisting of amoxycillin-
loaded ion-exchange resin encapsulated in mucoadhesive polymers (polycarbophil and 
Carbopol 934) were prepared. 
As reported in this review, the drug delivery systems have an important role on prevention 
of NSAID related or H.pylori induced gastric ulcers. 
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